Australian Wearable Patch Could End Painful IVF Blood Tests

Women undergoing IVF treatment may soon say goodbye to multiple painful blood tests, thanks to a sensor patch that monitors hormones through the skin.

Building on groundbreaking work by Prof. Sharath Sriram, Western Australia's Chief Scientist, Melbourne startup Symex Labs is developing a wearable device that detects progesterone and oestradiol without needles or clinic visits. The patch uses microscopic microneedles to access hormones in the fluid between skin cells, producing an electrical signal that tells doctors when patients are ready for embryo transfer.

"The hormones bind to the sensor, producing an electrical signal that informs IVF clinicians if the patient is ready for embryo transfer," said Symex co-founder Edgar Charry. Women could monitor their hormone levels from home, checking results through their phones instead of making repeated trips to the clinic.

The technology has attracted $2.5 million in backing from the Federal Government, the University of Melbourne, Monash IVF, RMIT, and Breakthrough Victoria. That kind of support reflects the real need for this innovation.

Monash IVF Research Director Mark Green highlighted how the sensor could particularly help women in regional areas who currently drive hours for each blood test. The time, money, and stress savings could make IVF treatment more accessible for thousands of Australians facing fertility challenges.

Prof. Sriram's work at RMIT University laid the foundation for this medical breakthrough. Known for translating advanced nanoelectronics and sensor technology into healthcare solutions, he's built a reputation for making science fiction real.

The Ripple Effect

The sensor's impact could reach far beyond IVF clinics. Symex co-founder Muhammad Umer noted the device could monitor polycystic ovary syndrome, perimenopause, and menopause, offering personalised hormone tracking through consumer health apps.

Women managing various hormonal conditions could gain unprecedented insight into their bodies without constant medical appointments. That kind of empowerment transforms healthcare from something done to patients into something they control.

RMIT Deputy Vice-Chancellor Research and Innovation Distinguished Prof. Calum Drummond called the project a perfect example of research creating real-world impact. The team expects to begin the first human pilot study within 18 months, with commercial availability targeted for early 2028.

For the estimated one in six Australian couples facing fertility challenges, this small patch represents enormous hope.